<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="A/CK/GD/178/04 (H5N1) (GD178) viruses than the commercial neuraminidase (NA) inhibitor" exact="oseltamivir" post="in our prior study. Lycorine demonstrates outstanding antiviral activity"/>
 <result pre="al., 2017; Hu et al., 2017). M2 inhibitors, such as" exact="amantadine" post="and ramantadine, cannot protect the host from virus infection"/>
 <result pre="its amino acid mutation (Wang et al., 2013). To date," exact="oseltamivir" post="is the only commercial drug effective in human, where"/>
 <result pre="antimalarial, anti-parasite, antioxidant, hepatoprotective, analgesic, anti-inflammatory activities, and inhibition of" exact="ascorbic acid" post="synthesis (Kim et al., 2008; Lamoral-Theys et al., 2009;"/>
 <result pre="protein kinase (STK10), and other proteins (8/71) were involved in" exact="adenosine" post="and guanine triphosphatase (ATP and GTP) activity-related pathways; other"/>
 <result pre="found that lycorine exhibits stronger anti-influenza activity against GD178 than" exact="oseltamivir" post="and retains vRNP in the nucleus (He et al.,"/>
 <result pre="hepatocellular carcinomaMolecular Cancer Therapeutics16122711272310.1158/1535-7163.MCT-17-049828974556 Yusuf et al. (2016)YusufMMohamedNMohamadSJanezicDDamodaranKVWahabHA2016H274Yâ€™s effect on" exact="oseltamivir" post="resistance: what happens before the drug enters the binding"/>
</results>
